On 22 May 2026, the European Medicines Agency (EMA) published a document titled 'Questions to EMA on midazolam', inviting stakeholders to submit queries regarding the medicine. The document aims to clarify regulatory and scientific aspects of midazolam, a benzodiazepine used for sedation, anesthesia, and seizure management. This initiative is part of EMA's ongoing efforts to engage with healthcare professionals, patients, and industry on specific products.
The document does not propose new regulatory measures or guidelines but rather serves as a platform for collecting questions that may inform future EMA communications or assessments. Midazolam is subject to EU-wide marketing authorizations and is included in the Union list of controlled substances due to its potential for abuse. The publication date of 22 May 2026 marks the start of a question-collection period, with EMA expected to provide responses in a subsequent document.
Impact on stakeholders For pharmaceutical companies holding marketing authorizations for midazolam, the Q&A process may clarify regulatory expectations and reduce uncertainty. Healthcare professionals and patients may benefit from clearer guidance on safe use, dosing, and risk management. National competent authorities could use the responses to harmonize their oversight. However, the document imposes no new obligations and does not alter existing legal frameworks, so the immediate impact is limited to information gathering.
Expected follow-up EMA will compile and answer the submitted questions, likely publishing a consolidated Q&A document in the coming months. Stakeholders are encouraged to submit their questions via the specified channels. No timeline for responses has been announced.
← Atlas › News › Health & Lifestyle